Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BKNDK
ADC Name
506E15-CysMab-DAPA-AURIX2
Synonyms
506E15 CysMab DAPA AURIX2
   Click to Show/Hide
Organization
Novartis AG
Drug Status
Investigative
Indication
In total 3 Indication(s)
Diffuse large B-cell lymphoma
Investigative
.
Hodgkin lymphoma
Investigative
.
Multiple myeloma
Investigative
.
Drug-to-Antibody Ratio
3.8
Antibody Name
Anti-CCR7 mAb 506E15
  Antibody Info 
Antigen Name
C-C chemokine receptor type 7 (CCR7)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
506E15.CysMab.DAPA.AURIX2 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.01
nM
CVCL_1170
Anaplastic large cell lymphoma
Half Maximal Inhibitory Concentration (IC50) 
0.01
nM
CVCL_3386
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.01 nM Positive CCR7 expression (CCR7+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Anaplastic large cell lymphoma DEL cells CVCL_1170
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.01 nM Positive CCR7 expression (CCR7+++/++)
Method Description
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.

   Click to Show/Hide
In Vitro Model Normal KE-97 cells CVCL_3386
References
Ref 1 Anti- CCR7 antibody drug conjugate.